The Global Non-Opioid Market in Pain Management 2007-2022

Visiongain believe that the market for non-opioid drugs is the fastest growing segments in pain management with a CAGR of 8.12% for the period 2006-2012. The brand new report entitled “The Global Non-Opioid Market in Pain Management” has highlighted a number of innovative pipeline developments that are set to shape the industry over the medium term.

Currently there are significant unmet needs in the treatment of pain, with great scope for more effective, safer and efficacious drugs. Furthermore, new drugs in this field have the potential to treat a range of conditions, with high potential revenues and life cycle benefits. Visiongain predicts that the non-opioid market will exhibit strong growth in revenues from 2007-2012, with significant investments being made by companies in the pharmaceutical industry, and with at least three blockbuster drugs by 2012.

- In-depth analysis of non-opioid market till 2012

- Plus forecasts and analysis of the medioum term non-opioid market to 2022

The Global Non-Opioid Market in Pain Management 2007 examines the global non-opioid market critically through a comprehensive review of available information. Sources include primary and secondary research - industrial databases, commercial news, published reports, economic research and consultation with experts. This information is not available anywhere else. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

With country-by-country focus on the markets of:

- US

- UK

- Germany

- Japan

- France

- Italy

- Spain

In particular, The Global Non-Opioid Market in Pain Management 2007 concentrates on the following essential aspects of the market:

• Discussion of the current pharmaceutical market

• Forecast of the worldwide pharmaceutical market from 2007-2022

• Drivers and restraints facing the non-opioid market

• Opportunities and threats facing the non-opioid market

• Growth of the non-opioid sector between 2007-2022

• Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012

• The potential of generics manufacturers to penetrate this market

• Pipeline developments with blockbuster potential

• Currently marketed drugs with blockbuster potential

• Discussion of unmet therapeutic needs and relative advantages of products

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for non-opioid drugs from 2007-2012

• To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2006-2012

• To determine key activities of leading companies

• To discover “hot” pipeline developments and up-and-coming products

• To determine the forces that influence the market for non-opioid products:

• Competitive characteristics of the market

• Drivers

• Restraints

• Strengths, weaknesses, opportunities and threats (SWOT analysis)

• To find out where the non-opioid market is heading - both technologically and commercially

Unique benefits to you when you order this report:

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

You should read this report today. Contact me know to order your copy.

PRICING

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only $5,998.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only $9,998.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only $13,998.00

November 2007
Table of Contents

Price
Department Licence 5 Users $5,998.00
Company-wide Intranet Licence $9,998.00
Over 2500 employees $13998.00